Advertisement
Advertisement
U.S. Markets close in 5 hrs 11 mins
Advertisement
Advertisement
Advertisement
Advertisement

MiMedx Group, Inc. (MDXG)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.6000-0.0100 (-0.28%)
As of 04:00PM EDT. Market open.
Advertisement

MiMedx Group, Inc.

1775 West Oak Commons Court, NE
Marietta, GA 30062
United States
770 651 9100
https://www.mimedx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees811

Key Executives

NameTitlePayExercisedYear Born
Mr. Peter Martin Carlson CPAChief Financial Officer787.81kN/A1964
Mr. William F. Hulse IVGen. Counsel & Chief Admin. Officer733.69kN/A1974
Dr. Rohit Kashyap Ph.D.Pres of Wound Care & Surgical741.29kN/A1971
Dr. Robert Benjamin Stein M.D., Ph.D.Pres of Regenerative Medicine & Biologics Innovation731.25kN/A1951
Mr. Timothy R. Wright MBACEO & DirectorN/AN/A1958
Mr. Scott M. TurnerSr. VP of Operations & ProcurementN/AN/A1965
Mr. William L. PhelanSr. VP & Chief Accounting OfficerN/AN/AN/A
Mr. John J. HowarthSr. VP of Investor RelationsN/AN/AN/A
Mr. Mark P. GravesSr. VP & Chief Compliance OfficerN/AN/A1966
Hilary DixonVP of Investor Relations & Corp. Strategic CommunicationsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.

Corporate Governance

MiMedx Group, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 6. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 4; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement